Robidoux's reelection comes as biosimilars get a lift from automatic switching policies in British Columbia and Alberta.
Biosimilars Canada, a national trade association representing biosimilar developers and other industry stakeholders, has reelected Michel Robidoux, the president and general manager of Sandoz Canada, to serve as chair of the Biosimilars Canada board.
In a statement announcing his reappointment, Robidoux praised the biosimilar switching policies implemented by British Columbia and Alberta in 2019. These policies require that patients with chronic conditions be transitioned to certain biosimilars under the oversight of their physician. The programs have achieved savings that proponents have said could be reinvested in health care to broaden access not only to biologics but also other therapies and services.
“Biosimilar medicines have an important role in supporting health care sustainability and patient care,” Robidoux said. “The implementation of biosimilar switching policies could save the Canadian health care system hundreds of millions of dollars.” Citing a 2020 report by the Ontario Drug Policy Research Network, the statement said that annual savings of $425.6 million for provincial drug plans is possible in Canada by switching patients from 3 of the top-selling reference biologics: Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab). “A similar magnitude of savings would be available for employer-sponsored benefit plans,” it said.
Biosimilars Canada is affiliated with the European trade group International Generic and Biosimilar Medicines Association and is a division of the Canadian Generic Pharmaceutical Association. The group also reelected Mike Woolcock to serve as vice chair of the board. Woolcock is a senior vice president at Apobiologix. Other companies represented by Biosimilars Canada include Auropharma, Fresenius Kabi, Pharmascience, Taro, Teva, and Viatris.
For an update on biosimilar savings in British Columbia from the perspective of Pacific Blue Cross, click here.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.